Skip to Content
You are currently on the new version of our website. Access the old version .
  • Review
  • Open Access

10 September 2026

36 Pages

Multilevel Mechanisms and Clinical Efficacy of Psilocybin in Depression Treatment: A Systematic Review

,
,
and
1
Institute for Chinese Medicine and Brain Science, Shandong University of Traditional Chinese Medicine, Ji’nan 250014, China
2
School of Health, Shandong University of Traditional Chinese Medicine, Ji’nan 250014, China
*
Author to whom correspondence should be addressed.
This article belongs to the Section Bioactives and Nutraceuticals

Abstract

Depression, characterized by persistent low mood and anhedonia, represents a prevalent affective disorder imposing substantial medical and economic burdens. Current first-line antidepressants are limited by delayed onset and treatment resistance. Psilocybin (PSI) has re-emerged as a promising therapeutic agent with rapid, sustained antidepressant effects. This systematic review was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidelines and prospectively registered with International Prospective Register of Systematic Reviews (PROSPERO) (CRD420261425626). Comprehensive searches of PubMed, Web of Science, and ScienceDirect identified studies published between January 2021 and March 2026 that examined the antidepressant mechanisms and clinical efficacy of PSI. Of 949 records screened, 46 original studies were included. We synthesized evidence across the molecular, cellular, neural circuit, and clinical dimensions. Our findings suggest that psilocin, the active metabolite, may exert antidepressant effects through multilevel mechanisms, including 5-hydroxytryptamine receptor 2A (5-HT2a) receptor activation, brain-derived neurotrophic factor (BDNF)-tropomyosin receptor kinase B(TrkB) signaling, hippocampal neurogenesis, and default mode network functional connectivity remodeling. Clinical trials confirm that single or limited-dose PSI (particularly 25 mg) rapidly and sustainably alleviates symptoms in treatment-resistant depression, with efficacy comparable or superior to that of escitalopram. This multilevel framework bridges mechanistic insights with clinical translation, supporting PSI as a novel therapeutic pathway for depression.

Article Metrics

Citations

Article Access Statistics

Multiple requests from the same IP address are counted as one view.